Document:

msci-ex10155_238.htm

Exhibit 10.155 

 

CONFIDENTIAL TREATMENT REQUESTED. *********** INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

 

A.N.: 130339

AMD_00220071.0

 

AMENDMENT

 

Date of Amendment: February 10, 2017

 

AMENDMENT (this “Amendment”) to the Index License Agreement for Funds (MSCI reference number IXF_00040) dated as of March 18, 2000 (as previously amended, the “Agreement”) is made by and between MSCI Inc. (formerly known as Morgan Stanley Capital International Inc.) (“MSCI”) and BlackRock Fund Advisors, a California corporation (as successor to Barclays Global Investors, N.A.) (“Licensee”).  Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement.

 

	
1.
	
Exhibit A of the Agreement is hereby amended to add the following Index:

 

	
 
	
•
	
MSCI Emerging Markets ex China Index

 

or such other indexes as agreed by Licensee and MSCI in writing.

 

	
2.
	
Licensee may use the Index set forth in Section 1 above solely with respect to the following Licensee fund (the “EM ex China ETF” which shall also be a “Fund” as such term is defined in the Agreement):

 

	
 
	
•
	
iShares MSCI Emerging Markets ex China ETF

 

or such other names as agreed by Licensee and MSCI in writing.

 

The EM ex China ETF shall be an exchange traded index fund listed on a national securities exchange located in the United States.

 

	
3.
	
Licensee shall pay MSCI a ********* license fee based on **************************************** ******************, which fee shall be calculated and payable on a **************.  The ********* license fee shall be calculated ************************************************************************  ******************************************************************************************* **************, as follows:

	
4.
	

		
	
 **************
	
*****************

	
******************
	
******************************** ****************************** ***********

	
******************* **********
	
******************************** ****************************** ***********

	
********************

***********
	
******************************* ****************************** ***********

	
*********************

**********
	
******************************* ****************************** ***********

	
*************
	
******************************* ****************************** ***********

 

1

A.N.: 130339

AMD_00220071.0

 

For the avoidance of doubt, the ********* license fees shall be calculated *************.  For example, ******* ********************************************************************************************* *********************************************************************************************

********************************************************************************************* *********************************************************************************************       **************************************************************************************************************************.

 

“Expense Ratio” shall mean the ****************************************** when dividing ******* *********************************************************************************************

******************************************************************************************** *************************************************************.

 

Notwithstanding anything to the contrary contained herein, if during any relevant period the Fund ************* **************** or if the Fund’s ********************************** or if the Fund has an *********************, the ********* licensee fee for the Fund shall ********************************* ****************************************************.

 

	
5.
	
Special Conditions:

 

	
 
	
a.
	
To the extent that this Amendment conflicts with the Agreement, this Amendment shall control.  No right or license of any kind is granted to Licensee except as expressly provided in the Agreement and this Amendment.

 

	
 
	
b.
	
MSCI may terminate this Amendment with respect to the Index set forth in Section 1 if, within one (1) year of the date of this Amendment, Licensee does not list the EM ex China ETF that is based on such Index.

 

	
 
	
c.
	
If Licensee delists the EM ex China ETF or changes the underlying Index for the EM ex China ETF, Licensee’s right to use the relevant Index set forth in Section 1 with respect to the EM ex China ETF shall automatically and immediately terminate.

 

	
 
	
d.
	
This Amendment shall be governed by, and construed in accordance with, the laws of the State of New York without regard to its conflict or choice of laws principles.

 

 

ACKNOWLEDGED AND AGREED

 

 

 

			
	
LICENSEE: BlackRock Fund Advisors.
	
 
	
MSCI Inc.

	
By /s/ Diane Lumley
	
 
	
By /s/ Alex Gil

	
Name Diane Lumley
	
 
	
Name Alex Gil

	
Title Managing Director
	
 
	
Title Executive Director

	
Date  Mar 9, 2017
	
 
	
Date Mar 10, 2017

 

2msci-ex10156_239.htm

Exhibit 10.156 

 

CONFIDENTIAL TREATMENT REQUESTED. *********** INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

A.N.: 130339

AMD_00219333.0

 

Amendment No. 1

This Amendment No. 1 (the “Amendment”) is entered into as of 6 April 2017 and is effective as of 6 April 2017 (“Effective Date”) by and between MSCI ESG Research LLC and BlackRock Fund Advisors (“Licensee”) pursuant to the Index License Agreement for Funds (MSCI reference number IXF_00040) dated as of March 18, 2000 (the “U.S. Agreement”) by and between MSCI Inc. (as successor to Morgan Stanley Capital International Inc.) and Licensee (as successor to Barclays Global Investors, N.A.); the U.S. Agreement, together with this Amendment, shall constitute the “Agreement”. 

 

Capitalized terms used but not defined in this Amendment shall have the meanings ascribed to them in the U.S. Agreement. 

 

*The parties agree that this Amendment is subject to the terms and conditions of the U.S. Agreement, all of which shall be incorporated hereunder, and which shall constitute the whole and standalone Agreement between Licensee and MSCI ESG Research LLC.  The parties agree, for the purposes of this Amendment, that MSCI ESG Research LLC shall be deemed to be “MSCI” (as such term is used in the U.S. Agreement) as if it had entered the U.S. Agreement in place of MSCI Inc.  For the avoidance of doubt, this Amendment shall not modify any other licenses granted to Licensee pursuant to the U.S. Agreement, or any other amendment to the U.S. Agreement between MSCI Inc. and Licensee.

 

	
1.
	
Indexes and Marks: 

 

Exhibit A of the U.S. Agreement is hereby amended to include only the following Indexes and Marks:

 

	
 
	
•
	
Bloomberg Barclays MSCI US Corporate ESG Focus Index, and

	
 
	
•
	
Bloomberg Barclays MSCI US Corporate 1-5 Year ESG Focus Index.

 

	
2.
	
Description of the Funds:

 

Exhibit B of the U.S. Agreement is hereby amended as follows:

 

	
 
	
a.
	
Licensee shall use the Indexes set forth in Section 1 above with respect to the following Licensee Funds (the “ESG ETFs”, which shall each respectively also be a “Fund” as such term is defined in the U.S. Agreement): 

 

	
 
	
•
	
iShares ESG USD Corporate Bond ETF

	
 
	
•
	
iShares ESG 1-5 Year USD Corporate Bond ETF 

 

Or such other name(s) as are agreed by Licensee and MSCI.

 

	
 
	
b.
	
The ESG ETFs shall be exchange traded index funds listed on a national securities exchange located in the United States.

1

 

A.N.:130339

AMD00219333.0

 

	
 
	
c.
	
Such primary listing(s) must occur within twelve months of the Effective Date of this Amendment. After such twelve month period, Licensee shall obtain MSCI’s prior written permission before the primary listing of the Fund(s) on any national securities exchange located in the United States.

 

	
 
	
d.
	
The Amendment: (i) does not give Licensee the right to create any futures, options or other derivatives based on any of the Indexes listed in this Amendment, and (ii) does not give Licensee the right to create any futures, options, or other derivatives of the Fund(s) without the prior written consent of MSCI. Notwithstanding the foregoing, Licensee may hold futures, options or other derivative securities as constituent holdings of the Fund(s).

 

	
 
	
e.
	
Licensee or any affiliate of Licensee is the asset manager of the Fund(s).

 

	
3.
	
License Fees: 

 

The first paragraph of Section 3 of the U.S. Agreement shall be replaced as follows:

 

	
 
	
a.
	
Each ******** Licensee shall pay to only MSCI **************: 

 

	
 
	
(i)
	
***************************************************************************** *******************

	
 
	
(ii)
	
*****************************************************************************  ***************************************************************************** ***************************************************************************** ******************. 

 

***********************************************, which shall be calculated on a ******** ****** on the last day of the **************** or, in the event of a termination of the Agreement or this Amendment, the effective date of such termination. ************************************** ****************************************, all license fees applicable to the Fund(s) shall be **** *************************************************************.

 

	
 
	
b.
	
Licensee shall, with the payment of the relevant ********* License Fees, provide to MSCI a written report that shall include the ******** and ********************************* License Fees due this Amendment, for the relevant period. The License Fee shall be paid in arrears to MSCI by the ********* **************************** and shall be accompanied by a statement from Licensee or its designee stating that such fees are accurate. ********************************************************** **************************************************************************************************************************************************************************** ************************************************.

 

	
4.
	
Miscellaneous:

 

	
 
	
a.
	
MSCI ESG Research LLC and Barclays Capital Inc. (or its successor, “Bloomberg/Barclays”) are parties to an agreement dated as of May 2, 2012 setting forth the licensing for the Indexes and Marks listed above. MSCI ESG Research LLC has full power and authority, including all necessary permissions and authorizations from Bloomberg/Barclays, to grant a license to the Licensee to use the Indexes and Marks listed above. Licensee hereby acknowledges and agrees that for the Indexes, Licensee has provided to MSCI certain specifications, designs, security screens or other instructions from Licensee, such as instructions for controversial weapon exclusion screening (the "Licensee Information").  Licensee represents and warrants that it has all rights, titles, licenses, permissions and approvals necessary to provide the Licensee Information to MSCI or Bloomberg/Barclays for purposes of calculating the Index and that 

2

 

A.N.: 130339

AMD_00219333.0

 

none of the Licensee Information infringes, violates, trespasses or in any manner contravenes or breaches any patent, copyright, trademark, license or other property or proprietary right or constitutes the unauthorized use or misappropriation of any trade secret of any third party.

 

	
 
	
b.
	
Licensee shall refer to an Index only by the name set forth in this Amendment.  No use or reference of the Index by Licensee shall imply that the Index is part of the standard family of indexes published by MSCI and/or Bloomberg/Barclays.  Further, Licensee agrees not to make any statement or take any action that expresses or implies that MSCI and/or Bloomberg/Barclays approves of, endorses or otherwise expresses any judgment or opinion regarding Licensee or its products or services.

 

	
 
	
c.
	
Notwithstanding anything to the contrary (including Section 2 of the U.S. Agreement), the term of this Amendment shall commence on the Effective Date set forth above and shall continue for 3 years (the “Initial Term”), unless earlier terminated as provided herein or in the U.S. Agreement. Thereafter, this Amendment shall renew for successive one-year periods (each, a “Renewal Term”) unless either party provides written notice to the other of its intent not to renew at least ninety (90) days prior to the end of the then-current Term (the Initial Term and Renewal Term(s), if any, shall be referred to as the “Term” herein). For the avoidance of doubt, this Amendment shall automatically terminate if the U.S. Agreement terminates or expires for any reason.

 

	
 
	
d.
	
Licensee agrees that the audit requirements under Section 3 of the U.S. Agreement also include a right of audit with respect to Licensee’s compliance with this Amendment, subject to MSCI complying with any confidentiality obligations set forth in the U.S. Agreement and any applicable regulatory obligations provided to MSCI in advance in writing, and provided that any such audit does not access any Confidential Information that would cause the Licensee to breach any contractual obligation of confidentiality it owes to its clients.

 

	
 
	
e.
	
In addition to the rights granted to MSCI in Section 4(c) of the U.S. Agreement and subject to the same notice requirements detailed therein, Licensee hereby acknowledges and agrees that MSCI and/or Bloomberg/Barclays may, and MSCI and/or Bloomberg/Barclays reserve the right in their discretion to, make changes in the titles, names, format, organization or content of the underlying parent index, including without limitation amending, enhancing or replacing index methodologies or index naming conventions governing the underlying parent index as well as any applicable security level attributes related to such underlying parent index.

 

	
 
	
f.
	
Licensee acknowledges and agrees that the Indexes, the Marks, and all intellectual property rights in respect thereof are the property of MSCI and/or Bloomberg/Barclays, their affiliates and information providers (as applicable), and that the use granted hereunder shall not be construed to vest in Licensee any rights except as expressly authorized herein. Licensee further acknowledges and agrees that Marks shall include Bloomberg/Barclays trade name, trademark and service mark rights (including Index names and other Bloomberg/Barclays marks referred to herein) and that Bloomberg/Barclays is entitled to the same rights and protections that MSCI is afforded under the U.S. Agreement, including Sections 6 through 9 of the U.S. Agreement.  

 

	
 
	
g.
	
The disclaimer under Section 10(b) shall be replaced as follows in respect of the Funds only:

 

THIS FUND IS NOT SPONSORED, ENDORSED, SOLD OR PROMOTED BY MSCI ESG RESEARCH LLC (“MSCI ESG RESEARCH”), BLOOMBERG INDEX SERVICES LIMITED (“BLOOMBERG”), OR BARCLAYS BANK PLC (“BARCLAYS”), ANY OF THEIR AFFILIATES, ANY OF THEIR INFORMATION PROVIDERS OR ANY OTHER THIRD PARTY (COLLECTIVELY, THE “INDEX PARTIES”) INVOLVED IN, OR RELATED TO, COMPILING, COMPUTING OR CREATING ANY BLOOMBERG BARCLAYS MSCI ESG INDEX (EACH, AN “INDEX”).  THE INDEXES ARE THE EXCLUSIVE PROPERTY OF MSCI ESG RESEARCH 

3

 

A.N.: 130339

AMD_00219333.0

 

AND BLOOMBERG (AND THEIR LICENSORS). “BLOOMBERG”, “BARCLAYS”, “MSCI ESG RESEARCH”, AND THE INDEX NAMES, ARE RESPECTIVE TRADE AND/OR SERVICE MARK(S) OF BLOOMBERG, BARCLAYS, MSCI ESG RESEARCH, OR THEIR AFFILIATES AND HAVE BEEN LICENSED FOR USE FOR CERTAIN PURPOSES BY [LICENSEE].  NONE OF THE INDEX PARTIES MAKES ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, TO THE ISSUER OR OWNERS OF THIS FUND OR ANY OTHER PERSON OR ENTITY REGARDING THE ADVISABILITY OF INVESTING IN FUNDS GENERALLY OR IN THIS FUND PARTICULARLY OR THE ABILITY OF ANY MSCI INDEX TO TRACK CORRESPONDING STOCK MARKET PERFORMANCE.  MSCI ESG RESEARCH, BLOOMBERG, BARCLAYS, OR THEIR AFFILIATES ARE THE LICENSORS OF CERTAIN TRADEMARKS, SERVICE MARKS AND TRADE NAMES AND OF THE MSCI INDEXES WHICH ARE DETERMINED, COMPOSED AND CALCULATED BY BLOOMBERG AND/OR MSCI ESG RESEARCH WITHOUT REGARD TO THIS FUND OR THE ISSUER OR OWNERS OF THIS FUND OR ANY OTHER PERSON OR ENTITY.  NONE OF THE INDEX PARTIES HAS ANY OBLIGATION TO TAKE THE NEEDS OF THE ISSUER OR OWNERS OF THIS FUND OR ANY OTHER PERSON OR ENTITY INTO CONSIDERATION IN DETERMINING, COMPOSING OR CALCULATING THE INDEXES.  NONE OF THE INDEX PARTIES IS RESPONSIBLE FOR OR HAS PARTICIPATED IN THE DETERMINATION OF THE TIMING OF, PRICES AT, OR QUANTITIES OF THIS FUND TO BE ISSUED OR IN THE DETERMINATION OR CALCULATION OF THE EQUATION BY OR THE CONSIDERATION INTO WHICH THIS FUND IS REDEEMABLE.  FURTHER, NONE OF THE INDEX PARTIES HAS ANY OBLIGATION OR LIABILITY TO THE ISSUER OR OWNERS OF THIS FUND OR ANY OTHER PERSON OR ENTITY IN CONNECTION WITH THE ADMINISTRATION, MARKETING OR OFFERING OF THIS FUND. 

 

ALTHOUGH THE INDEX PARTIES SHALL OBTAIN INFORMATION FOR INCLUSION IN OR FOR USE IN THE CALCULATION OF THE INDEXES FROM SOURCES CONSIDERED RELIABLE, NONE OF THE INDEX PARTIES WARRANTS OR GUARANTEES THE ORIGINALITY, ACCURACY AND/OR THE COMPLETENESS OF ANY INDEX OR ANY DATA INCLUDED THEREIN.  NONE OF THE INDEX PARTIES MAKES ANY WARRANTY, EXPRESS OR IMPLIED, AS TO RESULTS TO BE OBTAINED BY THE ISSUER OF THE FUND, OWNERS OF THE FUND, OR ANY OTHER PERSON OR ENTITY, FROM THE USE OF ANY INDEX OR ANY DATA INCLUDED THEREIN.  NONE OF THE INDEX PARTIES SHALL HAVE ANY LIABILITY FOR ANY ERRORS, OMISSIONS OR INTERRUPTIONS OF OR IN CONNECTION WITH ANY INDEX OR ANY DATA INCLUDED THEREIN. FURTHER, NONE OF THE INDEX PARTIES MAKES ANY EXPRESS OR IMPLIED WARRANTIES OF ANY KIND, AND THE INDEX PARITES HEREBY EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO EACH INDEX AND ANY DATA INCLUDED THEREIN.  WITHOUT LIMITING ANY OF THE FOREGOING, IN NO EVENT SHALL ANY OF THE INDEX PARTIES HAVE ANY LIABILITY FOR ANY DIRECT, INDIRECT, SPECIAL, PUNITIVE, CONSEQUENTIAL OR ANY OTHER DAMAGES (INCLUDING LOST PROFITS) EVEN IF NOTIFIED OF THE POSSIBILITY OF SUCH DAMAGES.

 

No purchaser, seller or holder of this security, product or fund, or any other person or entity, should use or refer to any MSCI ESG Research, Bloomberg or Barclays trade name, trademark or service mark to sponsor, endorse, market or promote this security without first contacting MSCI ESG Research to determine whether permission is required.  Under no circumstances may any person or entity claim any affiliation with MSCI ESG Research, Bloomberg or Barclays without prior written permission.

 

	
 
	
h.
	
The disclaimer required under Section 10(c) shall be replaced as follows in respect of the Funds only:

4

 

A.N.: 130339

AMD_00219333.0

 

The funds or securities referred to herein are not sponsored, endorsed, or promoted by MSCI ESG Research, Bloomberg or Barclays, and MSCI ESG Research, Bloomberg and Barclays bear no liability with respect to any such funds or securities or any index on which such funds or securities are based.  The [Prospectus] contains a more detailed description of the limited relationship MSCI ESG Research, Bloomberg and Barclays have with [Licensee] and any related funds.

 

	
 
	
i.
	
Licensee hereby acknowledges and agrees that Bloomberg/Barclays is considered a third party beneficiary of this Agreement. 

 

	
 
	
j.
	
Notwithstanding any other provision in this Agreement, the Licensee shall not be required to pay twice for the same loss under this Agreement. 

 

	
 
	
k.
	
With respect to this Amendment only, the indemnification provision under Section 11(a) of the U.S. Agreement shall be deleted in its entirety and replaced as follows: 

 

“(a)Licensee shall indemnify, defend and hold harmless MSCI and its parent, subsidiaries, affiliates, Bloomberg/Barclays and its parent, subsidiaries and affiliates, and their officers, directors, employees and agents (each, an “Indemnitee”) against any and all judgments, damages, costs or losses of any kind (including reasonable attorney’s and experts’ fees) as a result of claims or actions brought by third parties against any Indemnitee which arise from any act or omission of Licensee which constitutes a breach of this Agreement or is in any manner related to the Funds (except with respect to any claim or action alleging that Licensee’s or Funds’ use of the Indexes and Marks violates or infringes any trademark, service mark, copyright or other proprietary right of any person not a party to this Agreement); provided, however, that (i) MSCI notifies Licensee promptly of any such claim or action, and (ii) Licensee shall have no liability to an Indemnitee if such judgments, damages, costs or losses are attributable to any breach of the Agreement, negligent act or omission by any Indemnitee with respect to this Agreement.  Licensee shall bear all expenses in connection with the defense and/or settlement of any such claim or action. MSCI shall have the right, at its own expense, to participate in the defense of any claim or action against which an Indemnitee is indemnified hereunder; provided, however, it shall have no right to control the defense, consent to judgment, or agree to settle any claim or action, without the written consent of Licensee.  Licensee, in the defense of any such claim, except with the written consent of MSCI, shall not consent to entry of any judgment or enter into any settlement which (i) does not include, as an unconditional term, the grant by the claimant to each relevant Indemnitee of a release of all liabilities in respect of such claims or (ii) otherwise adversely affects the rights of an Indemnitee.  This provision shall survive the termination of this Agreement.”

 

	
 
	
l.
	
MSCI and/or Bloomberg/Barclays may collect data generated as a result of use of the Indexes by Licensee provided and/or made available to MSCI and/or Bloomberg/Barclays as a result of the Agreement and/or concerning Licensee usage of the Indexes and Licensee acknowledges and hereby agrees that MSCI and/or Bloomberg/Barclays may use such data, including Licensee’s contact and delivery information to: (i) allow for delivery of the Indexes to Licensee and for reporting purposes between MSCI and/or Bloomberg/Barclays; (ii) enable MSCI and/or Bloomberg/Barclays to better tailor products to meet its customers’ particular requirements; (iii) improve the Indexes; and (iv) provided always that such data has been anonymized, for any other purpose.

 

	
 
	
m.
	
The “Notice” addresses under Section 13 shall be replaced as follows:

 

Notice to MSCI:         MSCI ESG Research LLC

7 World Trade Center

250 Greenwich Street, 49th Floor

New York, NY 10017, USA

5

 

A.N.: 130339

AMD_00219333.0

 

Attn: MSCI Finance Department

Fax: 212-809-1213

 

with a copy to (which shall not constitute notice hereunder):

 

MSCI ESG Research LLC

7 World Trade Center

250 Greenwich Street, 49th Floor

New York, NY 10017, USA

Attn: General Counsel

Fax: 212-804-2906

 

Notice to Licensee:    BlackRock Fund Advisors

400 Howard Street

San Francisco, CA 94105

Attn: U.S. Legal and Compliance Group

Fax: (415) 618-1025

 

with a copy to (which shall not constitute notice hereunder):

 

BlackRock Fund Advisors

55 East 52nd Street

New York, NY 10055

Attn: U.S. Legal and Compliance Group

 

 

 

The parties agree that this Amendment forms an integral part of, and is subject to all the terms and conditions of the Agreement.

 

			
	
MSCI ESG Research LLC
	
 
	
BlackRock Fund Advisors

	
By: /s/ Alex Gil
	
 
	
By: /s/ Diane Lumley

	
Name: Alex Gil
	
 
	
Name: Diane Lumley

	
Title: Executive Director
	
 
	
Title: Managing Director

 

 

6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00279-of-00352.parquet"}]]